356 related articles for article (PubMed ID: 32705923)
21. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
Patel KK; Isufi I; Kothari S; Foss F; Huntington S
Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
[TBL] [Abstract][Full Text] [Related]
22. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
Betts KA; Thuresson PO; Felizzi F; Du EX; Dieye I; Li J; Schulz M; Masaquel AS
J Comp Eff Res; 2020 Oct; 9(14):1003-1015. PubMed ID: 33028076
[No Abstract] [Full Text] [Related]
23. Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
Topp MS; Eradat H; Florschütz A; Hochhaus A; Wrobel T; Walewski J; Knopinska-Posluszny W; Kanate AS; Lech-Maranda E; Brunnberg U; Chitra S; Nielsen TG; Sellam G; Shivhare M; Lossos IS
J Cancer Res Clin Oncol; 2023 Feb; 149(2):811-817. PubMed ID: 35182224
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.
Kawasaki N; Tomita M; Yamashita-Kashima Y; Yoshimura Y; Yoshiura S
Leuk Lymphoma; 2023 Dec; 64(12):1938-1948. PubMed ID: 37548343
[TBL] [Abstract][Full Text] [Related]
25. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
26. [Cohort study of efficacy and safety of polatuzumab vedotin combined with immunochemotherapy in patients with relapse/refractory diffuse large B cell lymphoma].
Wu JQ; Liu YY; Li F; Wu XZJ; Yao ZH; Kong FC; Zhou WL; Tang WY; Teng Y; Feng JF
Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(25):1985-1990. PubMed ID: 34225420
[No Abstract] [Full Text] [Related]
27. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
Liao MZ; Lu D; Lu T; Gibiansky L; Deng R; Samineni D; Dere R; Lin A; Hirata J; Shen BQ; Zhang D; Li D; Li C; Miles D
Adv Drug Deliv Rev; 2024 Apr; 207():115193. PubMed ID: 38311111
[TBL] [Abstract][Full Text] [Related]
29. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma.
Yasuda H; Kaga N; Taka H; Ochiai T; Yamana T; Miura Y; Ishii M; Sasaki M; Ando J; Ando M
Cancer Chemother Pharmacol; 2024 Mar; 93(3):265-268. PubMed ID: 37750932
[TBL] [Abstract][Full Text] [Related]
30. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Amaya ML; Jimeno A; Kamdar M
Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
[TBL] [Abstract][Full Text] [Related]
31. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Malecek MK; Watkins MP; Bartlett NL
Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753
[TBL] [Abstract][Full Text] [Related]
32. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
Shinmura K; Okubo S; Kadota S; Nakayama H; Sakurai A; Kurosawa S; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2023 Jan; 102(1):223-225. PubMed ID: 36394579
[No Abstract] [Full Text] [Related]
33. Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial.
Felizzi F; Launonen A; Thuresson PO
Pharmacoecon Open; 2023 Jan; 7(1):37-46. PubMed ID: 35900699
[TBL] [Abstract][Full Text] [Related]
34. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
Bourbon E; Salles G
Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
[TBL] [Abstract][Full Text] [Related]
35. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
[No Abstract] [Full Text] [Related]
36. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
Smith SD; Lopedote P; Samara Y; Mei M; Herrera AF; Winter AM; Hill BT; Shadman M; Ujjani C; Lynch RC; Jacobson CA; Kim AI; Caimi P; Milano F; Gopal AK
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):170-175. PubMed ID: 33431309
[TBL] [Abstract][Full Text] [Related]
37. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Avivi I; Perry C; Segman Y; Amit O; Bar-On Y; Katz OB; Gold R; Ribakovsky E; Avigdor A; Vainstein V; Goldschmidt N; Ringelstein-Harlev S; Horowitz NA; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Vezker M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Luttwak E; Herishanu Y; Ram R
Ann Hematol; 2022 Apr; 101(4):755-762. PubMed ID: 35083525
[TBL] [Abstract][Full Text] [Related]
38. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Choi Y; Diefenbach CS
Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
[TBL] [Abstract][Full Text] [Related]
39. A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma.
Liu Y; Wuxiao Z; Kong F; Feng J; Wu J; Yao Z; Zhou W; Li F
Ann Transl Med; 2022 Oct; 10(19):1070. PubMed ID: 36330404
[TBL] [Abstract][Full Text] [Related]
40. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
Varma G; Wang J; Diefenbach C
Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
